Update on Screening Breast MRI in High-Risk Women

Magnetic Resonance Imaging Clinics of North America

Volumn 18, Issue 2, 2010, Pages 241-247

  Boetes, C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast; Cancer; Increased risk; MRI; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTRAST ENHANCEMENT; COWDEN SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PREMENOPAUSE; REVIEW; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH;

AGED; BREAST NEOPLASMS; DERMATITIS, CONTACT; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAGNETIC RESONANCE IMAGING; MASS SCREENING; MIDDLE AGED; MUTATION; RISK ASSESSMENT; RISK FACTORS;

EID: 77952975751     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2010.02.003     Document Type: Review

References (42)

1. Fracheboud J., Otto S.J., van Dijck J.A., et al. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004, 91(5):861-867.
2. Kerlikowske K., Grady D., Barclay J., et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996, 276(1):33-38.
3. Tilanus-Linthorst M.M., Obdeijn I.M., Bartels K.C., et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000, 63(1):53-60.
4. Claus E.B., Schildkraut J.M., Thompson W.D., et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77(11):2318-2324.
5. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336(20):1401-1408.
6. American Society of Clinical Oncology American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21(12):2397-2406.
7. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996, 14(5):1730-1736. [discussion: 37-40].
8. Claus E.B., Risch N., Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994, 73(3):643-651.
9. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81(24):1879-1886.
10. Euhus D.M., Smith K.C., Robinson L., et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002, 94(11):844-851.
11. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
12. Mann R.M., Kuhl C.K., Kinkel K., et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008, 18(7):1307-1318.
13. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62(3):676-689.
14. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002, 94(18):1365-1372.
15. Warner E., Foulkes W., Goodwin P., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999, 91(14):1241-1247.
16. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56(1):265-271.
17. Edwards S.M., Kote-Jarai Z., Meitz J., et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003, 72(1):1-12.
18. Ozcelik H., Schmocker B., Di Nicola N., et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16(1):17-18.
19. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20(6):1480-1490.
20. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
21. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997, 349(9064):1505-1510.
22. Lakhani S.R., Van De Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20(9):2310-2318.
23. Tilanus-Linthorst M., Verhoog L., Obdeijn I.M., et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002, 102(1):91-95.
24. Foulkes W.D., Brunet J.S., Stefansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004, 64(3):830-835.
25. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48(18):5358-5362.
26. Nichols K.E., Malkin D., Garber J.E., et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10(2):83-87.
27. Achatz M.I., Hainaut P., Ashton-Prolla P. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. Lancet Oncol 2009, 10(9):920-925.
28. Eng C. Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol 1998, 12(3):701-710.
29. Giardiello F.M., Brensinger J.D., Tersmette A.C., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119(6):1447-1453.
30. Athma P., Rappaport R., Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92(2):130-134.
31. Wolden S.L., Hancock S.L., Carlson R.W., et al. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000, 18(4):765-772.
32. Arpino G., Laucirica R., Elledge R.M. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005, 143(6):446-457.
33. Morris E.A., Liberman L., Ballon D.J., et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003, 181(3):619-626.
34. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93(21):1633-1637.
35. Kurian A.W., Sigal B.M., Plevritis S.K. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010, 28(2):222-231.
36. Hemann M.T., Rudolph K.L., Strong M.A., et al. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol Biol Cell 2001, 12(7):2023-2030.
37. Stoutjesdijk M.J., Boetes C., Jager G.J., et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001, 93(14):1095-1102.
38. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437.
39. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
40. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317-1325.
41. Sardanelli F., Podo F., D'Agnolo G., et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007, 242(3):698-715.
42. Weinstein S.P., Localio A.R., Conant E.F., et al. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 2009, 27(36):6124-6128.